SCHEMBL2768547

SCHEMBL2768547

COC(=O)Cc1c(C)cn2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.47
KDM4E B2RXH2 9/20 0.42
ALDH1A1 P00352 8/20 0.42
HPGD P15428 6/20 0.42
GAA P10253 6/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 3/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 2/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.40
ATM Q13315 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17476301 0.82 PLA2G2A (0.41) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL2772073 0.79 GAA (0.42) EGFRKDM4EALDH1A1GAAMEN1
SCHEMBL2754107 0.79 CYP4F2 (0.47) EGFRKDM4EALDH1A1HPGDGAA
SCHEMBL7012344 0.77 MMP1 (0.42) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL8127143 0.75 ALDH1A1 (0.47) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL1436027 0.74 HRH3 (0.40) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL7167047 0.73 ALDH1A1 (0.40) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL17484544 0.71 KDM4E (0.38) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL7168520 0.71 TAAR1 (0.39) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL27735043 0.71 ALDH1A1 (0.45) KDM4EALDH1A1HPGDGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093751-A1 Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2010-04-15 US disclosed
EP-1910357-B1 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LTD (GB) 2010-04-14 EP disclosed
US-20090163534-A1 Indolizine Derivatives ARGENTA DISCOVERY LIMITED (GB) 2009-06-25 US disclosed
CN-101243086-A Indolizine derivatives and their use as CRTH2 antagonists ARGENTA DISCOVERY LTD (GB) 2008-08-13 CN disclosed
EP-1910357-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS Argenta Discovery Limited (GB) 2008-04-16 EP disclosed
WO-2006136859-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093751-A1 Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor HRH2, HRH4, HRH1 EGFR 318/4885KDM4E 4791/4885ALDH1A1 1384/4885
US-20090163534-A1 Indolizine Derivatives HRH4, HRH2, NR1H2 EGFR 403/4885KDM4E 4750/4885ALDH1A1 3086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.